Swiss-French implant cuts blood sugar, aids weight loss

Researchers from Switzerland and France have engineered a body-implantable device designed to monitor patient blood sugar levels. The innovation aims to regulate glucose concentrations and facilitate weight reduction without the need for pharmaceutical intervention.

Global healthcare costs drive innovation

The team highlights the economic burden of Type 2 diabetes, noting that global healthcare systems currently spend approximately three trillion dollars combating this condition, along with associated obesity and metabolic disorders. According to the inventors, they developed a wireless implant capable of maintaining normal blood sugar levels while contributing to weight loss.

Professor Martin Fussenegger of the Swiss Federal Institute of Technology, alongside other scientists, points out that numerous chronic diseases—including diabetes, obesity, and various thyroid disorders—require continuous administration of insulin and other hormonal or protein-based medications. These drug molecules decompose relatively quickly after ingestion, causing significant inconvenience and forcing patients to take regular doses.

Nanoparticle technology replaces drugs

These challenges have motivated biologists and engineers to create implantable devices that either release medications slowly into the body or produce them using cell cultures. However, keeping these "living factories" viable remains a complex task, as it requires protecting them from immune cell attacks and ensuring adequate oxygen supply to the cell cultures.

Fussenegger and his colleagues solved this issue through a distinct approach: they invented a material that absorbs electrical energy to break down glucose in the patient's blood. This substance consists of platinum-coated gold nanoparticles deposited on a graphite substrate and covered by a protective polymer layer. A computer continuously measures glucose levels in the bloodstream to control this structure.

Successful trials in diabetic mice

Tests conducted on mice suffering from Type 1 diabetes and obesity demonstrated the material's efficacy. One hour after implanting the device, blood sugar levels returned to normal ranges. The animals' bodies shifted from glucose metabolism to fat burning, resulting in weight loss and the normalization of lipid metabolism within six weeks.

The researchers believe similar methods could be used to control blood sugar levels in individuals with Type 2 diabetes.